Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677381 | 1.00 | LAP3 (0.49) | LAP3TAAR1MEN1KMT2AEPHX1 | |
| SCHEMBL9668003 | 1.00 | LAP3 (0.49) | LAP3TAAR1MEN1KMT2AEPHX1 | |
| SCHEMBL13431344 | 0.78 | LAP3 (0.54) | LAP3TAAR1EPHX1ANPEPTRPA1 | |
| SCHEMBL9667088 | 0.78 | LAP3 (0.48) | LAP3ANPEPACP3ALDH1A1LMNA | |
| SCHEMBL8741187 | 0.76 | TAAR1 (0.54) | LAP3TAAR1MEN1KMT2AEPHX1 | |
| SCHEMBL8842853 | 0.76 | TAAR1 (0.54) | LAP3TAAR1MEN1KMT2AEPHX1 | |
| SCHEMBL10714483 | 0.75 | LAP3 (0.56) | LAP3ANPEPTRPA1ACP3ALDH1A1 | |
| SCHEMBL11167921 | 0.75 | LAP3 (0.70) | LAP3TAAR1EPHX1ANPEPSLC6A2 | |
| SCHEMBL11821898 | 0.74 | POLB (0.46) | LAP3MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL11821901 | 0.74 | POLB (0.46) | LAP3MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | claimed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010111136-A2 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| US-4931591-A | Novel 5-amino-4-hydroxyvaleryl derivatives | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | LAP3 2161/4885TAAR1 1435/4885MEN1 4203/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | LAP3 4494/4885TAAR1 712/4885MEN1 3647/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LAP3 738/4885TAAR1 230/4885MEN1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.